Last reviewed · How we verify

Loceryl NL 12 weeks

Galderma R&D · FDA-approved active Small molecule

Loceryl is a topical antifungal that inhibits fungal sterol synthesis by blocking lanosterol 14α-demethylase, disrupting the fungal cell membrane.

Loceryl is a topical antifungal that inhibits fungal sterol synthesis by blocking lanosterol 14α-demethylase, disrupting the fungal cell membrane. Used for Onychomycosis (fungal nail infection), Dermatophyte and yeast infections of nails.

At a glance

Generic nameLoceryl NL 12 weeks
SponsorGalderma R&D
Drug classAllylamine antifungal
TargetLanosterol 14α-demethylase (CYP51)
ModalitySmall molecule
Therapeutic areaDermatology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Amorolfine, the active ingredient in Loceryl, is an allylamine antifungal that interferes with ergosterol biosynthesis in fungal cell membranes. By inhibiting the cytochrome P450-dependent enzyme lanosterol 14α-demethylase, it causes accumulation of toxic sterol precursors and depletion of ergosterol, leading to fungal cell death. This mechanism makes it effective against dermatophytes, yeasts, and non-dermatophyte molds.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results